Integra LifeSciences Holdings (IART) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.009x

Based on the latest financial reports, Integra LifeSciences Holdings (IART) has a cash flow conversion efficiency ratio of 0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.80 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Integra LifeSciences Holdings fund operations to measure how many days the company can operate on defensive assets alone.

Integra LifeSciences Holdings - Cash Flow Conversion Efficiency Trend (1995–2025)

This chart illustrates how Integra LifeSciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Integra LifeSciences Holdings Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integra LifeSciences Holdings ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Paymentus Holdings, Inc.
NYSE:PAY
0.052x
IRSA Inversiones Y Representaciones
NYSE:IRS
-0.026x
Nanjing Sciyon Automation Group Co Ltd
SHE:002380
0.148x
Bank Pan Indonesia Tbk
JK:PNBN
0.020x
PCBL LIMITED
NSE:PCBL
0.205x
Jintuo Technology Co Ltd
SHG:603211
N/A
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
-0.041x
Wuxi Zhenhua Auto Parts Co. Ltd.
SHG:605319
0.081x

Annual Cash Flow Conversion Efficiency for Integra LifeSciences Holdings (1995–2025)

The table below shows the annual cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Integra LifeSciences Holdings (IART) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.04 Billion $50.38 Million 0.048x -42.33%
2024-12-31 $1.55 Billion $129.38 Million 0.084x -5.01%
2023-12-31 $1.59 Billion $139.96 Million 0.088x -39.86%
2022-12-31 $1.80 Billion $264.47 Million 0.147x -20.96%
2021-12-31 $1.68 Billion $312.43 Million 0.185x +37.82%
2020-12-31 $1.51 Billion $203.83 Million 0.135x -17.63%
2019-12-31 $1.42 Billion $231.43 Million 0.163x +12.55%
2018-12-31 $1.38 Billion $199.68 Million 0.145x +21.93%
2017-12-31 $962.31 Million $114.54 Million 0.119x -14.14%
2016-12-31 $839.67 Million $116.41 Million 0.139x +10.26%
2015-12-31 $751.44 Million $94.48 Million 0.126x +11.45%
2014-12-31 $704.32 Million $79.46 Million 0.113x +41.94%
2013-12-31 $670.18 Million $53.27 Million 0.079x -29.91%
2012-12-31 $517.77 Million $58.72 Million 0.113x -46.45%
2011-12-31 $492.64 Million $104.33 Million 0.212x +0.29%
2010-12-31 $499.96 Million $105.57 Million 0.211x -34.41%
2009-12-31 $444.88 Million $143.24 Million 0.322x +55.33%
2008-12-31 $350.21 Million $72.59 Million 0.207x +14.79%
2007-12-31 $260.43 Million $47.03 Million 0.181x -25.42%
2006-12-31 $296.16 Million $71.70 Million 0.242x +23.43%
2005-12-31 $289.82 Million $56.85 Million 0.196x +54.92%
2004-12-31 $307.82 Million $38.98 Million 0.127x -2.37%
2003-12-31 $268.53 Million $34.83 Million 0.130x +0.39%
2002-12-31 $247.60 Million $31.98 Million 0.129x +67.89%
2001-12-31 $204.06 Million $15.70 Million 0.077x +183.43%
2000-12-31 $53.78 Million $-4.96 Million -0.092x -240.18%
1999-12-31 $38.00 Million $2.50 Million 0.066x +121.08%
1998-12-31 $31.40 Million $-9.80 Million -0.312x -41.43%
1997-12-31 $35.80 Million $-7.90 Million -0.221x -27.99%
1996-12-31 $46.40 Million $-8.00 Million -0.172x +46.43%
1995-12-31 $17.40 Million $-5.60 Million -0.322x --

About Integra LifeSciences Holdings

NASDAQ:IART USA Medical Devices
Market Cap
$1.34 Billion
Market Cap Rank
#7906 Global
#2275 in USA
Share Price
$17.20
Change (1 day)
-2.88%
52-Week Range
$8.90 - $17.90
All Time High
$76.63
About

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more